Tonix (NASDAQ: TNXP) director receives grant of 22,700 stock options

Rhea-AI Filing Summary

Tonix Pharmaceuticals Holding Corp. director David L. Grange received a grant of stock options covering 22,700 shares of common stock. The options have an exercise price of $13.28 per share, vest on the earlier of one year from grant or the 2027 annual stockholders meeting, and expire in 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider GRANGE DAVID L

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	22,700	$0.00	--

Holdings After Transaction: Stock Option — 22,700 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 22,700 options Exercise price: $13.28 per share Expiration date: May 12, 2036 +1 more

4 metrics

Options granted 22,700 options Stock option award to director on May 12, 2026

Exercise price $13.28 per share Strike price for Tonix common stock under the option

Expiration date May 12, 2036 Option term end date for granted stock options

Underlying shares 22,700 shares Tonix common stock underlying the stock options

Key Terms

Stock Option, 2026 Stock Incentive Plan, Annual Meeting of Stockholders, Grant, award, or other acquisition

4 terms

Stock Option financial

"security_title: "Stock Option" and underlying_security_title: "Common Stock""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

2026 Stock Incentive Plan financial

"The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan"

Annual Meeting of Stockholders financial

"vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders"

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GRANGE DAVID L

(Last) (First) (Middle)

C/O TONIX PHARMACEUTICALS HOLDING CORP

200 CONNELL DRIVE, SUITE 3100

(Street)

BERKELEY HEIGHTS NEW JERSEY 07922

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tonix Pharmaceuticals Holding Corp. [ TNXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$13.28	05/12/2026		A		22,700		05/12/2027(1)	05/12/2036	Common Stock	22,700	$0.00(1)	22,700	D

Explanation of Responses:

1. The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan, and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders.

	/s/ Jessica Morris, Attorney-in-Fact	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Tonix (TNXP) report for David L. Grange?

Tonix reported that director David L. Grange received a grant of 22,700 stock options. These options relate to Tonix common stock and were reported as a compensation award, not an open-market purchase or sale of existing shares.

What is the exercise price of the new Tonix (TNXP) stock options?

The newly granted Tonix stock options have an exercise price of $13.28 per share. This is the price at which the director can buy Tonix common stock when the options are exercised, subject to vesting and expiration terms.

When do David L. Grange’s Tonix (TNXP) options vest?

The options vest on the earlier of the one-year anniversary of the grant date or Tonix’s 2027 Annual Meeting of Stockholders. This means vesting depends either on time elapsed or on the timing of that specific shareholder meeting.

When do the newly granted Tonix (TNXP) stock options expire?

The options granted to David L. Grange expire on May 12, 2036. After that expiration date, the options can no longer be exercised to purchase Tonix common shares at the agreed exercise price of $13.28.

Under which plan were the Tonix (TNXP) options to David L. Grange granted?

The options were granted pursuant to Tonix’s 2026 Stock Incentive Plan. This plan governs equity-based compensation awards, including stock options, granted to eligible participants such as directors and other service providers.

How many Tonix (TNXP) derivative securities does David L. Grange hold after this grant?

Following the reported transaction, David L. Grange holds 22,700 stock options. These options each relate to one share of Tonix common stock, reflecting his full derivative position shown in this Form 4 filing.